Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis

Inclusion Criteria: * Definite infective endocarditis according to the 2023 Duke ISCVID criteria or confirmed by the endocarditis team if the endocarditis was classified as possible * Prosthetic valve endocarditis * At least one positive blood culture due to Staphylococcus sp (S. aureus or CoNS) * After the first positive blood culture, at least one negative blood culture (after a minimum of 72 hours of incubation) * Infective endocarditis due to Staphylococcus sp (S. aureus or coagulase negative staphylococci) susceptible to rifampin * Antistaphylococcal treatment for endocarditis introduced less than 14 days ago. We do not consider all antibiotic received before the first positive blood culture * Age ≥ 18-year-old * Informed, written consent obtained from patient or from patient's near in kin * Patient insured under a health insurance scheme * Patient with adequate contraceptive measure Exclusion Criteria: * Presence of cardiovascular implanted electronic device with suspected device-related IE without removal of the device * Expected duration of follow-up \<6 months at the time of randomization * Patient moribund (expected to die in next 48 hours with or without treatment) * Patients already receiving more than 72 hours of rifampin for the endocarditis treatment prior to randomization * Positive blood cultures less than 72 hours before randomization * Medical history of infective endocarditis in the last 3 months * True allergy to rifampin or a severe intolerance to rifampin * Contraindication to rifampin * Patients requiring treatment contraindicated or not recommended with rifampin or incompatible with the inducer effect of rifampicin according to the marketing authorisation. * ALAT increase greater than 3 times the upper laboratory range * Extreme weight (\< 45 kg or \> 150 kg) * Patients with confirmed prosthetic vascular graft infection or orthopedic-device-related infection * Patients treated with rifampin for infections other than endocarditis, such as tuberculosis * Pregnancy or breastfeeding woman * Inclusion in another drug clinical trial * Patients who have already been included in the study for a previous episode of endocarditis * Patients under court protection, guardianship or trusteeship * Patients who do not speak or understand French language * Patient unable to collect information in a daily journal * Patient unable to understand a follow-up by phone contact